clinical trial · NCT05366855
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Generalized Pustular PsoriasisDouble-blind 200 mg imsidolimabPlaceboOpen-label 200 mg imsidolimabStandard of Care (SOC)Imsidolimab 750 mg IV/200 mg SC
brief summary
This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
started
Apr 21, 2022
primary completion
Jul 12, 2024
completion
Jul 12, 2024
last updated
Mar 27, 2026
detailed description
This study will also evaluate the pharmacokinetic (PK) profile of imsidolimab and explore the immunogenicity of imsidolimab in subjects with GPP.
official title
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol